FDA Approves Tavneos as Add-on Therapy for Severe MPA, GPA

FDA Approves Tavneos as Add-on Therapy for Severe MPA, GPA

308682

FDA Approves Tavneos as Add-on Therapy for Severe MPA, GPA

The U.S. Food and Drug Administration (FDA) has approved Tavneos (avacopan) as an add-on therapy for people with severe active microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two most common forms of ANCA-associated vasculitis. The approval comes after an advisory committee narrowly supported avacopan’s approval in the U.S., prompting ChemoCentryx to file an amended application with additional data. Tavneos is the first approved treatment for AAV in over a decade, and marks the first FDA approval of…

You must be logged in to read/download the full post.